Reviews Dexlansoprazole Delayed Release Capsules


No reviews yet.

Dexilant Drug Description
Dexilant (formerly Kapidex)
(dexlansoprazole) Delayed Release Capsules
DRUG DESCRIPTION
The active ingredient in DEXILANT (dexlansoprazole) delayed release capsules
is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylj methyl} sulfinyl]-7H-benzimidazole,
a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer
of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its empirical
formula is: C16H14F3N3O2S, with a molecular weight of 369.36. The structural
formula is:







Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.
Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.
DEXILANT is supplied as a dual delayed release formulation in capsules for
oral administration. The capsules contain dexlansoprazole in a mixture of two
types of enteric-coated granules with different pH-dependent dissolution profiles
[see CLINICAL PHARMACOLOGY].
DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&C Blue No. 2 and aluminum lake; gray contains ferric oxide and aluminum lake; and both contain titanium dioxide.Last reviewed on RxList: 7/29/2010




Dexilant Drug Description
Dexilant (formerly Kapidex)
(dexlansoprazole) Delayed Release Capsules
DRUG DESCRIPTION
The active ingredient in DEXILANT (dexlansoprazole) delayed release capsules
is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylj methyl} sulfinyl]-7H-benzimidazole,
a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer
of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its empirical
formula is: C16H14F3N3O2S, with a molecular weight of 369.36. The structural
formula is:







Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.
Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.
DEXILANT is supplied as a dual delayed release formulation in capsules for
oral administration. The capsules contain dexlansoprazole in a mixture of two
types of enteric-coated granules with different pH-dependent dissolution profiles
[see CLINICAL PHARMACOLOGY].
DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&C Blue No. 2 and aluminum lake; gray contains ferric oxide and aluminum lake; and both contain titanium dioxide.Last reviewed on RxList: 7/29/2010




Dexilant Drug Description
Dexilant (formerly Kapidex)
(dexlansoprazole) Delayed Release Capsules
DRUG DESCRIPTION
The active ingredient in DEXILANT (dexlansoprazole) delayed release capsules
is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylj methyl} sulfinyl]-7H-benzimidazole,
a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer
of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its empirical
formula is: C16H14F3N3O2S, with a molecular weight of 369.36. The structural
formula is:







Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.
Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.
DEXILANT is supplied as a dual delayed release formulation in capsules for
oral administration. The capsules contain dexlansoprazole in a mixture of two
types of enteric-coated granules with different pH-dependent dissolution profiles
[see CLINICAL PHARMACOLOGY].
DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&C Blue No. 2 and aluminum lake; gray contains ferric oxide and aluminum lake; and both contain titanium dioxide.Last reviewed on RxList: 7/29/2010




Dexilant Drug Description
Dexilant (formerly Kapidex)
(dexlansoprazole) Delayed Release Capsules
DRUG DESCRIPTION
The active ingredient in DEXILANT (dexlansoprazole) delayed release capsules
is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylj methyl} sulfinyl]-7H-benzimidazole,
a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer
of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its empirical
formula is: C16H14F3N3O2S, with a molecular weight of 369.36. The structural
formula is:







Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.
Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.
DEXILANT is supplied as a dual delayed release formulation in capsules for
oral administration. The capsules contain dexlansoprazole in a mixture of two
types of enteric-coated granules with different pH-dependent dissolution profiles
[see CLINICAL PHARMACOLOGY].
DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&C Blue No. 2 and aluminum lake; gray contains ferric oxide and aluminum lake; and both contain titanium dioxide.Last reviewed on RxList: 7/29/2010




Dexilant Drug Description
Dexilant (formerly Kapidex)
(dexlansoprazole) Delayed Release Capsules
DRUG DESCRIPTION
The active ingredient in DEXILANT (dexlansoprazole) delayed release capsules
is (+)-2-[(R)-{[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-ylj methyl} sulfinyl]-7H-benzimidazole,
a compound that inhibits gastric acid secretion. Dexlansoprazole is the R-enantiomer
of lansoprazole (a racemic mixture of the R- and S-enantiomers). Its empirical
formula is: C16H14F3N3O2S, with a molecular weight of 369.36. The structural
formula is:







Dexlansoprazole is a white to nearly white crystalline powder which melts with decomposition at 140°C. Dexlansoprazole is freely soluble in dimethylformamide, methanol, dichloromethane, ethanol, and ethyl acetate; and soluble in acetonitrile; slightly soluble in ether; and very slightly soluble in water; and practically insoluble in hexane.
Dexlansoprazole is stable when exposed to light. Dexlansoprazole is more stable in neutral and alkaline conditions than acidic conditions.
DEXILANT is supplied as a dual delayed release formulation in capsules for
oral administration. The capsules contain dexlansoprazole in a mixture of two
types of enteric-coated granules with different pH-dependent dissolution profiles
[see CLINICAL PHARMACOLOGY].
DEXILANT is available in two dosage strengths: 30 mg and 60 mg, per capsule. Each capsule contains enteric-coated granules consisting of dexlansoprazole (active ingredient) and the following inactive ingredients: sugar spheres, magnesium carbonate, sucrose, low-substituted hydroxypropyl cellulose, titanium dioxide, hydroxypropyl cellulose, hypromellose 2910, talc, methacrylic acid copolymers, polyethylene glycol 8000, triethyl citrate, polysorbate 80, and colloidal silicon dioxide. The components of the capsule shell include the following inactive ingredients: hypromellose, carrageenan and potassium chloride. Based on the capsule shell color, blue contains FD&C Blue No. 2 and aluminum lake; gray contains ferric oxide and aluminum lake; and both contain titanium dioxide.Last reviewed on RxList: 7/29/2010





Other reviews about Dexlansoprazole Delayed Release Capsules on wordpress

FDA Approves KAPIDEX (dexlansoprazole) Delayed-Release Capsules For The Treatment Of GERD
  by maciekmaciek5
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX™ (dexlansoprazole) delayed release […]


FDA Approves KAPIDEX (dexlansoprazole) Delayed-Release Capsules For The Treatment Of GERD
  by maciekmaciek5
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX™ (dexlansoprazole) delayed release […]


Now, if we only knew what kind
  by ovshlkeywvabygy
Thus does unjust suspicion follow even the most blameless for, as the poet says, Who shall escape calumny? Half A minute more and it would pass over and […]


says I, slipping the rose between the
  by bnacqmkmqnby
She was dressed in a white nightgown, yards of gauzy material that billowed around her body. The salver was given him by the Earl of Pembroke in memory […]



Other reviews about Dexlansoprazole Delayed Release Capsules on web:

Learn about the prescription medication Kapidex Delayed Release Capsules (Dexlansoprazole Delayed Release Capsules), drug uses, dosage, side effects, drug interactions ... Kapidex Delayed Release Capsules (Dexlansoprazole Delayed Release ...


All about Dexlansoprazole Delayed-Release Capsules. View complete and up to date Dexlansoprazole information - part of the Drugs.com trusted medication database. Dexlansoprazole Delayed-Release Capsules Facts and Comparisons at ...


Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA ... FDA Approves KAPIDEX (dexlansoprazole) Delayed-Release Capsules ...


KAPIDEX is supplied as a dual delayed release formulation in capsules for oral administration. The capsules contain dexlansoprazole in a mixture of two types of enteric-coated ... Kapidex Capsule, Delayed Release drug information | MIMS USA


Osaka, Japan, January 31,2009 and Deerfield, Ill., January 30, 2009 – – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North ... FDA Approves KAPIDEX™ (dexlansoprazole) delayed release capsules ...


Deerfield, Ill. – February 23, 2009 – Takeda Pharmaceuticals North America, Inc. today announced that KAPIDEX™ (dexlansoprazole) delayed release capsules are now available in ... KAPIDEX™ (dexlansoprazole) delayed release capsules Now ...


KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now Available for the Treatment of GERD DEERFIELD, Ill., Feb. 23 /PRNewswire/ -- Takeda Pharmaceuticals North ... KAPIDEX(TM) (dexlansoprazole) delayed release capsules Now ...


Learn about Kapidex Delayed Release Capsules (Dexlansoprazole Delayed Release Capsules) - Side Effects, Drug Interactions, Pictures, Patient Information on RxList Kapidex Delayed Release Capsules (Dexlansoprazole Delayed Release ...


KAPIDEX (dexlansoprazole) delayed release capsules, previously known by the development code TAK-390MR, is a proton pump inhibitor (PPI), which decreases acid production by turning ... FDA Approves KAPIDEX(TM) (Dexlansoprazole) Delayed Release ...


FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD First proton pump inhibitor (PPI) with a Dual Delayed Release(TM) (DDR ... FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release ...





Featured Reviews

Reviews Triazolam

Halcion Drug Description Halcion® (triazolam) Tablets, USP CIV DRUG DESCRIPTION What are the possible side effects of triazolam (Halcion)? Triazolam may cause a severe allergic reaction. Stop taking triazolam and get emergency...
Read More  |  Review This
Reviews Isoflurane

Forane Drug Description FORANE (isoflurane, USP) Liquid For Inhalation DRUG DESCRIPTION FORANE (isoflurane, USP), a nonflammable liquid administered by vaporizing, is a general inhalation anesthetic drug. It is 1-chloro-2, 2,2-trifluoroethyl ...
Read More  |  Review This
Reviews Permax

Permax Drug Description DRUG DESCRIPTION What are the possible side effects of pergolide (Permax)? Stop taking pergolide and seek emergency medical attention or contact your doctor immediately if you experience any of the following...
Read More  |  Review This
Reviews Acamprosate Calcium

Campral Drug Description CAMPRAL® (acamprosate calcium) Delayed-Release Tablets DRUG DESCRIPTION What are the possible side effects of acamprosate (Campral)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Targretin Gel

Targretin Gel Drug Description Targretin® (bexarotene) Gel 1% DRUG DESCRIPTION What are the possible side effects of bexarotene topical (Targretin Topical)? Serious side effects are not likely to occur. Stop using bexarotene...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....